Jake King Blog | Talkmarkets | Page 1
A leading online destination for actionable equity research in healthcare.
Contributor's Links: PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically complicated companies and equities that are grossly over- or under-valued. We offer regular market ... more

Articles

Latest Posts
1 to 11 of 11 Posts
Your 30-Second Primer On This Week's Hottest IPO, Spark Therapeutics
Spark Therapeutics (ONCE) lists publicly today, joining companies like bluebird bio (BLUE) and Avalanche (AAVL) as yet another emerging gene therapy player.
On Bluebird Bio After A Glimpse Of Preliminary Lentiglobin Data
Last week, preliminary data for Bluebird Bio's Lentiglobin were released as part of the abstract dump for ASH in December. Here's what you need to know.
ASH 2014 Abstracts Are About To Hit: Here Are Some Of The Names To Follow
One of the biggest events in healthcare annually, the American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. Here's a primer on the stocks to watch.
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock
GlobeImmune IPO’d in June to little fanfare and has underperformed the biotech sector considerably since then. A key driving event in the next six months should put it back on the radar.
Being Early On An Early Asset: Trillium May Be A Diamond In The Rough Immunotherapy Stock
Trillium Therapeutics is an immuno-oncology company developing novel cancer therapeutics. Their primary target, the CD47 antigen, is generating significant attention from industry and academia alike.
Sarepta Hits Another Roadblock Prior To Eteplirsen New Drug Application
On Monday morning, Sarepta Therapeutics (SRPT) held a teleconference concerning regulatory updates for Eteplirsen, the company's lead drug candidate for Duchenne Muscular Dystrophy.
Pfizer Drops Remoxy: Durect And Pain Therapeutics Suffer
Pain Therapeutics and Durect announced on Monday morning that Pfizer will discontinue development of Remoxy (Extended-Release oxycodone) and will return all rights to Pain Therapeutics.
Tekmira And J&J’s Ebola Drugs Advance Towards Deployment In West Africa
Tekmira Pharmaceuticals (TKMR) and European drug developer Bavarian Nordic (BAVA.CO) are receiving significant attention in early trading on Wednesday morning with announcements that their two distinct approaches to Ebola, a therapeutic and vaccine respectively, are advancing.
With Latest Data, Investors Again Compare Synergy To The Billion-Dollar Ironwood Pharma
Synergy Pharmaceuticals (SGYP) is getting some much-needed love with phase 2 data, presented at a medical meeting on Monday, for the company's lead drug candidate, plecanatide in Irritable Bowel Syndrome (IBS-C).
Illumina Puts Up Yet Another Glowing Quarter
Illumina (ILMN) yet again posted great quarterly numbers, surpassing consensus on revenue and earnings.
FDA Continues To Quash Interest In Repros Therapeutics
FDA put the brakes on Repros Therapeutics (RPRX) on Friday when it indicated that an upcoming meeting would not be the pre-NDA meeting investors expected. The stock dropped 40% in early trading.
1 to 11 of 11 Posts